HOWL News and Press, Werewolf Therapeutics Inc. From 03/23/23

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors – – Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patient...

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body&#x...

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body&#x...

Summary Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 trial called ABILITY. A February 2023 update tells us MDNA stock has been able to increase the dose of MDNA11 without issues so far. The ABILITY trial is set to produce mor...

Gainers: Lucira Health ( LHDX ) +357% . ContraFect ( CFRX ) +75% . Moolec Science ( MLEC ) +29% . Werewolf  ( HOWL ) +14% . The Pennant Group ( PNTG ) +16% . Losers: Genprex ( GNPX ) -17% . ETAO Internationl ( ET...

WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Secon...

Summary Shares of immuno-oncology concern Werewolf Therapeutics are down 80% from their April 2021 IPO pricing as a lack of clinical data has negatively impacted results. That dynamic will start to change as two of its assets enter the clinic, with a readout expected for Interleukin-2 c...

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16 th at the SVB...

Stock Market Down? Insiders Are Buying Penny Stocks We’ve talked about how penny stocks tend to move independently of the broader markets. But there has been particular attention placed on specific stocks that insiders seem to like. There’s no guarantee that buying from corp...

Healthcare and life sciences focused investment management firm RA Capital along with its managing partners Peter Kolchinsky and Rajeev Shah have raised their active stake in cancer-focused biopharma Werewolf Therapeutics ( NASDAQ: HOWL ). RA Capital Management, Peter Kolchinsky and R...